GlassScriptPhysician profile
Irina Muni
NPI 1215958301
$2,951.56
in general payments reported to CMS, 2019-2025
31 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,461 · 2020: $258 · 2021: $26.74 · 2023: $68.16 · 2024: $627 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $769.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $218.58 | 2019-2024 | Airsupra, Bevespi Aerosphere |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.78 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.12 | 2019-2020 | |
| Amgen INC. | $168.57 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Astellas Pharma US INC | $161.28 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $138.47 | 2019-2024 | Trelegy Ellipta |
| Abbott Laboratories | $134.99 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $105.15 | 2019-2020 | |
| Lilly USA, LLC | $100.08 | 2019-2023 | Mounjaro |
| Actelion Pharmaceuticals US, INC. | $81.80 | 2024-2025 | Opsumit, Uptravi |
| Scilex Pharmaceuticals INC. | $73.37 | 2019 | |
| Avanir Pharmaceuticals, INC. | $58.37 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $55.11 | 2019-2020 | |
| Pfizer INC. | $52.01 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48.64 | 2021-2024 | |
| Allergan, INC. | $39.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.20 | 2019 | |
| Biomerieux INC | $28.00 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Exact Sciences Corporation | $27.40 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $27.38 | 2019-2020 | |
| Dexcom, INC. | $26.97 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $23.42 | 2025 | Zoryve |
| Seqirus USA INC | $23.37 | 2025 | Flucelvax, Fluad |
| E.R. Squibb & Sons, L.L.C. | $23.36 | 2019 | |
| Eisai INC. | $23.33 | 2025 | |
| Amarin Pharma, INC. | $19.26 | 2019 | |
| Medtronic USA, INC. | $18.63 | 2019 | |
| Merck Sharp & Dohme LLC | $18.43 | 2025 | Gardasil 9, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $16.65 | 2024 | Trintellix |
| Hikma Pharmaceuticals USA | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Muni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.